当前位置:肿瘤瞭望>资讯>快讯>正文

2024 ESMO BC大幕拉开,这些研究数据将被披露!

作者:肿瘤瞭望   日期:2024/4/28 11:00:22  浏览量:3315

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

2024年欧洲肿瘤内科学会乳腺癌年会(ESMO BC)将于当地时间5月15日至17日在德国柏林召开。本届大会亮点众多,涵盖乳腺癌的靶向治疗、内分泌治疗、免疫治疗等,多项重磅研究结果将进行公布。《肿瘤瞭望》特将会议即将发布的重要研究进行汇总,以飨读者。

编者按:2024年欧洲肿瘤内科学会乳腺癌年会(ESMO BC)将于当地时间5月15日至17日在德国柏林召开。本届大会亮点众多,涵盖乳腺癌的靶向治疗、内分泌治疗、免疫治疗等,多项重磅研究结果将进行公布。《肿瘤瞭望》特将会议即将发布的重要研究进行汇总,以飨读者。
 
Proffered Paper session 1
 
时间:2024年5月15日16:45-17:55(当地时间)
地点:Berlin Hall
主席:Erika P.Hamilton(Nashville,United States of America),Masakazu Toi(Bunkyo-ku,Japan)
 
179O-Combination of olaparib,durvalumab and fulvestrant in patients with advanced ER-positive,HER2-negative breast cancer harboring homologous recombination repair(HRR)deficiency or microsatellite instability(MSI):results of the international phase II DOLAF trial.
国际II期DOLAF研究的结果:奥拉帕利、度伐利尤单抗、氟维司群联合治疗伴有同源重组修复(HRR)缺陷或微卫星不稳定性(MSI)的晚期ER+/HER2-乳腺癌患者
演讲时间:16:45-16:57
讲者:Séverine Guiu(Montpellier,Cedex 5,France)
 
180O-IMpassion132 double-blind randomised phase 3 trial of chemotherapy(CT)±atezolizumab(atezo)for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer(aTNBC)
3期随机双盲IMpassion132研究:化疗(CT)±阿替利珠单抗(atezo)治疗早期复发、不可切除的局部晚期或转移性三阴性乳腺癌(aTNBC)
演讲时间:16:57-17:09
讲者:Rebecca A.Dent(Singapore,Singapore)
 
181O-Interim analysis(IA)of the atezolizumab(atezo)+sacituzumab govitecan(SG)arm in patients(pts)with triple-negative breast cancer(TNBC)in MORPHEUS-pan BC:A Phase Ib/II study of multiple treatment(tx)combinations in pts with locally advanced/metastatic BC(LA/mBC)
MORPHEUS-pan BC[多药联合治疗(tx)局部晚期/转移性乳腺癌(LA/mBC)患者的Ib/II期研究]中期分析(IA):阿替利珠单抗(atezo)+sacituzumab govitecan(SG)治疗三阴性乳腺癌(TNBC)患者
演讲时间:17:09-17:21
讲者:Peter Schmid(London,United Kingdom)
 
Mini Oral session 1
 
时间:2024年5月16日08:30-10:00
地点:Munich Hall
主席:Peter A.Fasching(Erlangen,Germany)Thomas Bachelot(Lyon,France)Cristina Saura Manich(Barcelona,Spain)
 
182MO-Trastuzumab deruxtecan(T-DXd)vs Treatment of Physician’s Choice(TPC)in Patients(pts)With HER2+Metastatic Breast Cancer(mBC)Previously Treated With Trastuzumab Emtansine(T-DM1):Updated Overall Survival(OS)Results of the Randomized,Phase 3 DESTINY-Breast(DB-)02 Study
在既往接受过恩美曲妥珠单抗(T-DM1)治疗的HER2+转移性乳腺癌(mBC)患者(pts)中,对比德曲妥珠单抗(T-DXd)与医师选择的治疗(TPC)疗效:随机、3期DESTINY-Breast-02研究总生存期(OS)结果更新
演讲时间:08:30-08:35
讲者:Sung-Bae Kim(Seoul,Korea,Republic of)
 
267MO-Pooled Analysis of Trastuzumab Deruxtecan(T-DXd)Retreatment(RTx)After Recovery From Grade(Gr)1 Interstitial Lung Disease/Pneumonitis(ILD)
1级间质性肺疾病/肺炎(ILD)患者恢复后,再用德曲妥珠单抗(T-DXd)治疗(RTx)疗效汇总分析
演讲时间:08:35-08:40
讲者:Hope S.Rugo(San Francisco,United States of America)
 
LBA3-SOLTI-1507 IPATHER:Primary results of the phase Ib study of ipatasertib(IPAT)and dual anti-HER2 therapy with trastuzumab and pertuzumab(HP)in patients(pts)with PIK3CA mutant(mut)HER2+advanced breast cancer(ABC)
Ib期SOLTI-1507 IPATHER研究的主要结果:ipatasertib(IPAT)联合曲妥珠单抗、帕妥珠单抗(HP)双重抗HER2治疗PIK3CA突变(mut)的HER2+晚期乳腺癌(ABC)患者(pts)
演讲时间:08:40-08:45
讲者:Ana Mafalda Antunes De Melo e Oliveira(Barcelona,Spain)
 
183MO-Capivasertib and fulvestrant(F)for patients(pts)with aromatase inhibitor(AI)-resistant HR+/HER2-advanced breast cancer(ABC):second progression-free survival(PFS2)and time to first subsequent chemotherapy(TFSC)in the CAPItello-291 trial
Capivasertib联合氟维司群(F)用于芳香化酶抑制剂(AI)耐药的HR+/HER2-晚期乳腺癌(ABC)患者:CAPItello-291试验中,第二次无进展生存期(PFS2)和至首次后续化疗的时间(TFSC)
演讲时间:09:03-09:08
讲者:Hope S.Rugo(San Francisco,United States of America)
 
1MO-HER2DX assay and survival outcomes:an individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer
HER2DX检测和生存结果:2031例HER2阳性乳腺癌患者个体水平的荟萃分析
演讲时间:09:08-09:13
讲者:Guillermo Villacampa Javierre(Barcelona,Spain)
 
2MO-Dynamics of ESR1 mutation(ESR1m)circulating tumour DNA(ctDNA)in patients(pts)with estrogen receptor(ER)+HER2-metastatic breast cancer(mBC)receiving camizestrant or fulvestrant:Exploratory analyses from the SERENA-2 trial
SERENA-2试验的探索性分析:在接受camizestrant或氟维司群治疗的雌激素受体(ER)+、HER2-转移性乳腺癌(mBC)ESR1突变(ESR1m)患者中,循环肿瘤DNA(ctDNA)的动态变化
演讲时间:09:13-09:18
讲者:Ana Mafalda Antunes De Melo e Oliveira(Barcelona,Spain)
 
3MO-Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+,HER2-,node-positive,high-risk early breast cancer enrolled in monarchE
对纳入monarchE研究的HR+/HER2-、淋巴结阳性、高危早期乳腺癌患者的胚系BRCA1/2突变和罕见体细胞突变进行分析
演讲时间:09:36-09:41
讲者:Christine Desmedt(Leuven,Belgium)
 
4MO-Neoadjuvant letrozole and palbociclib versus chemotherapy in the NeoPAL study:a translational analysis
NeoPAL研究中来曲唑联合哌柏西利对比化疗新辅助治疗的疗效比较:一项转化分析
演讲时间:09:41-09:46
讲者:Paul H.Cottu(Paris,France)
 
Proffered Paper session 2
 
时间:2024年5月16日16:45-18:05
地点:Berlin Hall
主席:Suzette Delaloge(Villejuif,Cedex,France)Giuseppe Curigliano(Milan,Italy)
 
LBA2-Datopotamab deruxtecan(Dato-DXd)vs chemotherapy(CT)in pretreated,inoperable/metastatic HR+/HER2-breast cancer(BC):Additional safety analysis from TROPION-Breast01
Dato-DXd vs化疗(CT)在既往接受过治疗、不可手术/转移性HR+/HER2-乳腺癌(BC)中的比较:TROPION-Breast01的额外安全性分析
演讲时间:16:45-16:57
讲者:Komal Jhaveri(New York,United States of America)
 
266O-Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer:results from an international cohort study
辅助生殖技术在年轻乳腺癌BRCA携带者妊娠中的安全性:一项国际队列研究的结果
演讲时间:17:29-17:41
讲者:Matteo Lambertini(Genova,Italy)
 
109O-Adjuvant Endocrine Therapy for Premenopausal Invasive Lobular Carcinoma(ILC):Results from SOFT and TEXT phase III studies
SOFT和TEXT III期研究中绝经前浸润性小叶癌(ILC)的辅助内分泌治疗结局
演讲时间:17:41-17:53
讲者:Otto Metzger(Boston,United States of America)
 
Mini Oral session 2
 
时间:2024年5月17日08:30-10:05
地点:Hamburg Hall
主席:Elzbieta Senkus-Konefka(Gdansk,Poland),Matteo Lambertini(Genova,Italy),Yoon Sim Yap(Singapore,Singapore)
 
LBA1-Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer-Time to Event analysis from the GeparX 2×2 Randomized Clinical Trial
在两种不同白蛋白结合型紫杉醇方案的基础上加用地诺单抗作为原发性乳腺癌患者的新辅助治疗——GeparX 2×2随机临床试验至事件发生时间分析
演讲时间:08:30-08:35
讲者:Sibylle Loibl(Neu-Isenburg,Germany)
 
110MO-Statin use and early breast cancer survival:A Danish population-based cohort study using an emulated target trial approach
他汀类药物使用与早期乳腺癌生存率:一项基于丹麦人群的队列研究,采用模拟目标试验方法
演讲时间:08:35-08:40
讲者:Karl S.Harborg(Aarhus,Denmark)
 
111MO-Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer:Efficacy outcomes and key subgroups after 10 years of follow-up in the randomized phase 3 PANTHER trial
高危早期乳腺癌个体化剂量密集化疗与标准辅助化疗的比较:随机3期PANTHER试验10年随访后的疗效结局和关键亚组
演讲时间:08:40-08:45
讲者:Theodoros Foukakis(Stockholm,Sweden)
 
268MO-Safety of vaginal estrogen therapy after early-stage breast cancer:a nationwide population-based target trial emulation.
早期乳腺癌患者阴道雌激素治疗的安全性:一项基于全国人群的目标试验模拟
演讲时间:08:55-09:00
讲者:Elise Dumas(Paris,France)
 
269MO-The effects of exercise on sexual health and breast cancer-specific symptom burden in women with metastatic breast cancer:Results of the multinational randomized PREFERABLE-EFFECT trial
运动对转移性乳腺癌女性患者性健康和乳腺癌特异性症状负担的影响:多国随机PREFERABLE-EFFECT试验的结果
演讲时间:09:00-09:05
讲者:Martina E.Schmidt(Heidelberg,Germany)
 
270MO-An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients-Results of the validation study Phase IV EORTC QLQ-BR42
评估乳腺癌患者生活质量的EORTC问卷更新-EORTC QLQ-BR42验证研究的IV期结果
演讲时间:09:05-09:10
讲者:Vesna Bjelic-Radisic(Wuppertal,Germany)
 
112MO-Neoadjuvant study of 12 months of Abemaciclib plus Letrozole vs.Chemotherapy in HR+/HER2_ highly proliferative(Ki67_20%)breast cancer:CARABELA(GEICAM/2019-01)Trial
CARABELA(GEICAM/2019-01)试验:12个月的阿贝西利联合来曲唑治疗vs化疗新辅助治疗HR+/HER2-高度增殖(Ki67≥20%)的乳腺癌患者
演讲时间:09:25-09:30
讲者:Miguel Martin Jimenez(Madrid,Spain)
 
184MO-First-in-human phase 1/2a study of the first-in-class,next-generation CDK4-selective inhibitor PF-07220060 in combination with endocrine therapy(ET)in patients(pts)with HR+/HER2_ metastatic breast cancer(mBC)who progressed on prior CDK4/6 inhibitors(CDK4/6i):safety and efficacy update
首创、新一代CDK4选择性抑制剂PF-07220060联合内分泌治疗(ET)用于CDK4/6抑制剂经治的HR+/HER2-转移性乳腺癌:I/2a期人体研究的安全性和疗效数据首次更新
演讲时间:09:30-09:35
讲者:Timothy Yap(Houston,United States of America)
 
113MO-NATALEE update:Safety and treatment(tx)duration of ribociclib(RIB)+nonsteroidal aromatase inhibitor(NSAI)in patients(pts)with HR+/HER2_ early breast cancer(EBC)
NATALEE研究更新:瑞波西利+非甾体芳香酶抑制剂(NSAI)在HR+/HER2-早期乳腺癌患者中的安全性和治疗持续时间
演讲时间:09:35-09:40
讲者:Carlos H.Barrios(Porto Alegre,Brazil)

 

版面编辑:张靖璇  责任编辑:无医学编辑

本内容仅供医学专业人士参考


乳腺癌

分享到: 更多